Literature DB >> 7420683

Myasthenia gravis and penicillamine therapy of rheumatoid arthritis.

T Bocanegra, L R Espinoza, F B Vasey, B F Germain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7420683

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  Ocular toxicity from systemic drug therapy. An overview of clinically important adverse reactions.

Authors:  S I Davidson; I G Rennie
Journal:  Med Toxicol       Date:  1986 May-Jun

Review 2.  Induction of auto-immune syndromes by penicillamine therapy in rheumatoid arthritis and other diseases.

Authors:  I A Jaffe
Journal:  Springer Semin Immunopathol       Date:  1981

3.  Penicillamine-induced myasthenia in rheumatoid arthritis: its clinical and genetic features.

Authors:  J P Delamere; S Jobson; L P Mackintosh; L Wells; K W Walton
Journal:  Ann Rheum Dis       Date:  1983-10       Impact factor: 19.103

Review 4.  Ocular myasthenia gravis after D-penicillamine administration.

Authors:  L J Katz; R L Lesser; J R Merikangas; J P Silverman
Journal:  Br J Ophthalmol       Date:  1989-12       Impact factor: 4.638

Review 5.  Clinically important ocular reactions to systemic drug therapy.

Authors:  I G Rennie
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.